Pfizer to give out breast cancer drug free while awaiting NHS decision

Pharmaceutical firm says it will offer palbociclib to patients while regulator rules on whether it should be available on NHS

A drug described as one of the most important advances in treating breast cancer in the past 20 years is to be given to women in the UK for free while the medicines regulator decides whether it should be available on the NHS.

The National Institute for Health and Care Excellence’s provisional decision in February that palbociclib should not be routinely funded on the NHS in England was decried by patients but its final appraisal has been paused for the drug manufacturer Pfizer to present further clinical data.

In the meantime, Pfizer has said it will make palbociclib available free of charge. The drug in combination with another can stall the growth of the cancer for about 10 months in comparison with existing treatments.

Fiona Hazell, director of policy and engagement at the charity Breast Cancer Now, said: “This is an unexpected lifeline for thousands of women living with this type of breast cancer. We are delighted that Pfizer have listened to our campaigners and have found a way to enable patients to access this first-in-class drug in the short term.

“While only an interim measure, more than 16 women every day could have their lives changed by this drug during this window. Palbociclib can offer a large proportion of patients with incurable metastatic breast cancer significant extra time before their disease progresses – time that can be truly invaluable to them and their loved ones.”

She said anyone who thought they might be eligible should speak to their doctor, but also urged Nice to reach agreement with Pfizer on making it available on the NHS to anyone who needed it.

At the time of the draft guidance that recommended palbociclib be rejected, Dr Nicholas Turner, team leader in molecular oncology at the Institute of Cancer Research and consultant medical oncologist at the Royal Marsden in London, described the drug as “one of the most important advances in treating the most common type of breast cancer in 20 years”.

The ICR and Breast Cancer Now both urged Pfizer to reduce the price to allow it to be offered on the NHS. Nice said at the time that a full course of treatment would cost £79,560 and the benefits were “still not enough to make palbociclib cost effective at its current price”.

It estimated that about 5,500 people in England – out of 45,000 new diagnoses of breast cancer each year – would potentially be eligible for treatment with the drug.

Results of a trial in 666 women with advanced breast cancer, presented at the American Society of Clinical Oncology meeting in Chicago last June, showed that taking palbociclib in combination with letrozole increased progression-free survival for a median 24.8 months compared with 14.5 months for letrozole alone.

The free programme is expected to be open for a maximum of five months – closing six weeks after Nice issues final guidance on the drug, or on 30 September, whichever is earlier – with access being dependent on individual NHS trusts signing up to the scheme.

Pfizer said women who took up the offer would receive the full duration of treatment, regardless of Nice’s final decision.

A spokeswoman for the company said: “Pfizer believes women with metastatic breast cancer deserve access as soon as possible to this innovative medicine that has been shown to significantly increase progression-free survival.

“Acknowledging calls from physicians and patient groups across the UK for timely access to palbociclib, Pfizer has made the decision, in this instance, to provide palbociclib free of charge whilst the appraisal process continues.”


Haroon Siddique

The GuardianTramp

Related Content

Article image
Breast cancer drug approved for NHS use after price cut
Perjeta can help shrink breast cancer tumours before patients undergo surgery to remove them

Sarah Boseley Health editor

17, Nov, 2016 @12:01 AM

Article image
Charity calls for new breast cancer drug to be given to UK women
Palbociclib may slow progress of disease by 10 months but Breast Cancer Now fears Nice will deem it not cost-effective

Sarah Boseley in Chicago

06, Jun, 2016 @11:01 PM

Article image
Breast cancer drug Kadcyla is too expensive for the NHS – not to pay for it is the correct decision | Deborah Orr

Deborah Orr: The NHS watchdog, Nice, is being portayed as penny-pinching over its refusal to fund a hugely expensive new cancer drug. But shouldn't we be asking why its manufacturers want to charge so much?

Deborah Orr

25, Apr, 2014 @4:30 PM

Article image
UK regulator approves drug that could extend lives of breast cancer patients
National Institute for Health and Care Excellence gives NHS go-ahead to prescribe eribulin after new evidence shows drug may have ‘substantial’ benefits

Denis Campbell Health policy editor

03, Nov, 2016 @12:01 AM

Article image
Breast cancer screening error may affect thousands more
Invitation glitch could date back further than previously thought, says cancer specialist

Ben Quinn

25, May, 2018 @10:15 PM

Article image
Drugs watchdog condemns Roche for high price of breast cancer therapy

Regulator Nice unable to approve £90,000 drug exceeding NHS limit, but pharmaceuticals firm calls UK funding system 'broken'

Sarah Boseley, health editor

07, Aug, 2014 @11:01 PM

Breast cancer drug Kadcyla deemed 'too expensive' for NHS - video

The National Institute for Health and Care Excellence is too expensive for use on the NHS but Roche says it has already been picked up elsewhere

08, Aug, 2014 @11:25 AM

Article image
Breast cancer drug approved for NHS after maker agrees discount
Reversal of earlier rejection by Nice of abemaciclib – known as Verzenios – is welcomed by campaigners

Sarah Marsh

12, Aug, 2021 @5:00 AM

Article image
Anger over UK's failure to ban breast implants linked to 61 cancer cases
Exclusive: solicitors call for UK ban of textured variety associated with lymphoma

Sarah Boseley Health editor

07, Jan, 2020 @6:00 PM

Unpublished data shows breast cancer drug 'third less effective'

Drug trial involving 1,000 women given Herceptin shows drug is not effective as thought

Sarah Boseley, health editor

15, May, 2008 @11:30 PM